All In Biotech

Drug Trial Radar · NCT07318805

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-08032562 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

Dec 23, 2025

Primary completion

Apr 14, 2029

Study completion Apr 14, 2030

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jan 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This study is seeking participants that have advanced or metastatic breast cancer (BC), or advanced or metastatic colorectal cancer (CRC). All participants in this study will take the study medication (PF-08032562) as pill by mouth. This will be repeated for 28-day cycles. Depending on which part of the study participants are enrolled into, they will receive the study medication PF-08032562 alone or in combination with other anti-cancer medications. The study medication (PF-08032562) will be taken by mouth (PO) in combination with other anti-cancer medications given in the study clinic by intramuscular (IM) injection into the muscle or intravenous (IV) infusion that is directly injected into the veins at different times (depending on the treatment) during the 28-day cycle. The study may also test different schedules.

Conditions

  • Advanced Breast Cancer
  • Metastatic Breast Cancer (HR+/ HER2-)
  • Colorectal Cancer
  • Metastatic Colorectal Adenocarcinoma
  • Triple Negative Breast Cancer

Interventions

  • PF-08032562Drug

    Taken by mouth (PO)

  • FulvestrantDrug

    Selective Estrogen Receptor Degrader (SERD)

  • CetuximabDrug

    Monoclonal antibody (EGFR inhibitor)

  • FluorouracilDrug

    Part of FOLFOX chemotherapy regimen cytotoxic chemotherapy (antimetabolite and pyrimidine analog)

  • OxaliplatinDrug

    Part of FOLFOX chemotherapy regimen platinum based compound (alkylating agent)

  • LeucovorinDrug

    Part of FOLFOX chemotherapy regimen (folic acid analog)

  • BevacizumabDrug

    Monoclonal antibody (VEG-F inhibitor)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 (Dose Escalation): Number of participants with Dose-Limiting Toxicities (DLT)Time frame: Baseline up to 28 days
  2. Part 1 (Dose Escalation): Number of participants with laboratory abnormalitiesTime frame: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
  3. Part 1 (Dose Escalation): Incidence of Adverse Events (AEs)Time frame: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
  4. Part 2 (Dose Expansion): Objective Response Rate (ORR)Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

Locations

17 sites in 3 countries. Site status is shown where the registry gives one.

  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

    Duarte, California · Recruiting

  • START Midwest, LLC

    Grand Rapids, Michigan · Recruiting

  • Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy

    Long Island City, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center 53rd street.

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center - Main Campus

    New York, New York · Recruiting

  • The University of Texas MD Anderson Cancer Center - Conroe

    Conroe, Texas · Recruiting

  • The University of Texas - M.D. Anderson Cancer Center

    Houston, Texas · Recruiting

  • The University of Texas, MD Anderson Cancer Center - West Houston

    Houston, Texas · Recruiting

  • The University of Texas, MD Anderson Cancer Center - League City

    League City, Texas · Recruiting

  • START San Antonio

    San Antonio, Texas · Recruiting

  • The University of Texas, MD Anderson Cancer Center - Sugar Land

    Sugar Land, Texas · Recruiting

  • START Mountain Region

    West Valley City, Utah · Recruiting

  • CHU Poitiers

    Poitiers, France · Not yet recruiting

  • Gustave Roussy

    Villejuif, Val-de-marne, France · Not yet recruiting

  • Hospital Universitario HM Sanchinarro

    Madrid, Spain · Not yet recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona [barcelona], Spain · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.